Angiotensin Converting Enzyme Inhibitors are a group of medicines used to treat heart failure, high blood pressure (hypertension), or reduce myocardial infarction complications (myocardial infarction). These drugs are also useful in slowing the progression of kidney disease in patients with chronic kidney disease or kidney disease in diabetic patients. The mechanism of action of angiotensin converting enzyme inhibitors is to reduce the amount of angiotensin II produced. Angiotensin II has an effect on the body's blood pressure, blood volume and blood pressure.
Show report: https://www.transparencymarketresearch.com/angiotensin-converting-enzyme-inhibitors-market.html
Angiotensin converting enzyme inhibitors extend the blood vessels by reducing the amount of angiotensin II in the body. They also increase the amount of urine produced by the kidneys. This results in decreased kidney pressure, decreased blood volume and blood pressure. A decrease in aldosterone and noradrenaline levels results in inhibitors of angiotensin converting enzyme due to inhibition of angiotensin II, which helps to lower blood pressure. Angiotensin converting enzyme inhibitors also increase bradykinin, which extends the blood vessels, thereby lowering blood pressure. They also cause several side effects depending on the type of angiotensin converting enzyme inhibitor. Side effects include facial or airway edema (angioedema), decreased kidney function, dizziness, high potassium levels (hyperkalemia), dry cough and low blood pressure (hypotension).
An increase in the prevalence of high blood pressure is a major factor influencing the development of angiotensin converting enzyme inhibitors. According to the World Health Organization, more than 1 out of 5 adults suffer from high blood pressure around the world. Complications of high blood pressure cause approximately 9.4 million deaths each year worldwide. An increase in heart failure also drives the market for angiotensin converting enzyme inhibitors. According to the Center for Disease Control and Prevention (CDC), approximately 5.7 million adults in the US suffer from heart failure each year, nearly half of whom die within five years of diagnosis.
Request a report brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=41111
The worldwide market for angiotensin converting enzyme inhibitors can be segmented based on the type of disease, dosage form and distribution channel. As for the type of disease, the angiotensin converting enzyme inhibitor market can be divided into heart failure, high blood pressure (hypertension), heart attack, and kidney disease. Based on the dosage form, the global market for angiotensin converting enzyme inhibitors may be included in oral tablets and oral solution. Based on the distribution channel, the angiotensin converting enzyme inhibitor market may be included in online pharmacies, retail pharmacies, and pharmacy hospitals.
Geographically, the global market for angiotensin converting enzyme inhibitors can be segmented into Latin America, Asia, the Pacific, Europe, North America and the Middle East and Africa. North America had the largest market share in angiotensin converting enzyme inhibitors in 2016. Growth in heart failure, stroke, and high blood pressure led to the market for angiotensin converting enzyme inhibitors in the region. Europe had the second largest market share in 2016. Increased renal disease and high blood pressure in the region contribute to market growth in the region. The market for angiotensin converting enzyme inhibitors in the Asia Pacific region is expected to result from increased government initiatives in the healthcare sector, particularly in countries such as India and China. The global market for angiotensin converting enzyme inhibitors in the Middle East and Africa is expected to be stimulated by government initiatives in the area of health care. The market for angiotensin converting enzyme inhibitors in Latin America predicts strong growth in the forecast period due to government heart disease initiatives in the region.
Key players in the market for angiotensin converting enzyme inhibitors include Bristol-Myers Squibb, Par Pharmaceutical Companies, Inc., UCB, Inc., Pfizer, Inc. and AstraZeneca.